Kalaris Therapeutics, Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| – | +450.7% | +166.0% | -22.7% | -98.6% | -14.5% | +3,456.7% | +2.7% | |
| – | +403.0% | +183.8% | -29.9% | -98.5% | -14.5% | +3,456.7% | +0.2% | |
| – | +144.7% | +100.8% | +64.4% | -98.5% | +3.6% | +3,632.7% | -17.1% | |
| – | +405.1% | +182.6% | -30.4% | -98.8% | +3.6% | +3,632.7% | -0.3% | |
| – | +85.4% | -19.6% | -88.9% | – | – | – | – | |
| – | +376.3% | -0.2% | +245.4% | -44.3% | +41.5% | -89.2% | +719.3% | |
| – | +143.7% | +35.0% | +207.9% | -85.0% | -30.7% | +32.9% | +85.4% | |
| – | – | +5.3% | +104.1% | – | – | – | – | |
| – | +311.8% | +52.9% | +768.2% | -67.0% | -14.4% | -89.5% | +418.6% | |
| – | – | – | – | – | – | – | – | |
| – | +463.5% | +190.3% | -36.2% | -113.4% | – | – | -30.4% | |
| – | – | – | – | – | – | – | – | |
| – | +0.0% | -58.7% | +133.4% | +22.1% | +35.7% | +10.7% | +204.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.